Q2 2016 13F Holders as of 30 Jun 2016
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49.6M
-
Number of holders
-
107
-
Total 13F shares, excl. options
-
31.8M
-
Shares change
-
+1.3M
-
Total reported value, excl. options
-
$948M
-
Value change
-
+$39.6M
-
Put/Call ratio
-
2.6
-
Number of buys
-
60
-
Number of sells
-
-52
-
Price
-
$29.79
Significant Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q2 2016
145 filings reported holding PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock as of Q2 2016.
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) has 107 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 31.8M shares
of 49.6M outstanding shares and own 64.09% of the company stock.
Largest 10 shareholders include ADAGE CAPITAL PARTNERS GP, L.L.C. (5.69M shares), FMR LLC (4.87M shares), ORBIMED ADVISORS LLC (2.96M shares), JANUS CAPITAL MANAGEMENT LLC (2.54M shares), VANGUARD GROUP INC (1.93M shares), Partner Fund Management, L.P. (1.47M shares), Point72 Asset Management, L.P. (1.42M shares), STATE STREET CORP (1.06M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.02M shares), and Capital Research Global Investors (677K shares).
This table shows the top 107 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.